Unknown

Dataset Information

0

Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer.

ABSTRACT:

SUBMITTER: Liam CK 

PROVIDER: S-EPMC5750146 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
| S-EPMC6143050 | biostudies-literature
Unknown EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer.
| S-EPMC5650459 | biostudies-literature
Unknown First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?
| S-EPMC5932412 | biostudies-literature
Unknown Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
| S-EPMC7209579 | biostudies-literature
Unknown Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study.
| S-EPMC8558340 | biostudies-literature
Unknown First-line treatment of advanced ALK-positive non-small-cell lung cancer.
| S-EPMC5217519 | biostudies-literature
Unknown The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
| S-EPMC6839103 | biostudies-literature
Unknown Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer.
| S-EPMC7577964 | biostudies-literature
Unknown First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors.
| S-EPMC3459550 | biostudies-literature
Unknown Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
| S-EPMC5569692 | biostudies-literature